Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography-Reference-Cited by-同舟云学术

Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography

Published:2021-03-18 Issue:4 Volume:18 Page:1690-1698
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Lu Weifei¹²,Cong Yiyang³,Yang Dongzhi⁴^ORCID,Chen Daiqin²,Yang Guoyu¹,Wang Yi²⁵,Van Dort Marcian E.²^ORCID,Ross Brian D.²^ORCID,Mazar Andrew P.⁶,Chu Bei-Bei¹,Hong Hao⁷^ORCID

Affiliation:

1. College of Animal Sciences and Veterinary Medicine, Henan Agriculture University, Zhengzhou, Henan 450002, China

2. Department of Radiology, University of Michigan, Ann Arbor, Michigan 48109-2200, United States

3. State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, 163 Xianlin Avenue, Nanjing 210093, China

4. Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China

5. School of Pharmacy, Department of Regenerative Medicine, Jilin University, Changchun, Jilin 130021, China

6. Monopar Therapeutics, Wilmette, Illinois 60091, United States

7. State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Key Laboratory of Molecular Medicine and School of Medicine, Medical School of Nanjing University, Nanjing 210093, China

Funder

National Cancer Institute

National Natural Science Foundation of China

Program for Innovative Talents and Entrepreneur in Jiangsu

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.0c01139

Reference36 articles.

1. Urokinase‐type plasminogen activator receptor ( uPAR ) as a promising new imaging target: potential clinical applications

2. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies

3. A Novel Nanoparticulate Formulation of Arsenic Trioxide with Enhanced Therapeutic Efficacy in a Murine Model of Breast Cancer

4. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications

5. Urokinase Type Plasminogen Activator and the Molecular Mechanisms of its Regulation in Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immuno-PET Imaging of TNF-α in Colitis Using ⁸⁹Zr-DFO-infliximab;Molecular Pharmaceutics;2022-08-30

2. Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer;Cancers;2022-01-19